Clonidine for Attention-Deficit/Hyperactivity Disorder: I. Efficacy and Tolerability Outcomes

 Editorship of Mina K. Dulcan, M.D.Members of the CAT Study Team are listed at the end of the article.This project was supported by NINDS grant 5R01 NS039087 (Dr. Sallee). Additional NIH support came from K23 MH065375 (Dr. Daviss) and K24 AA000301 (Dr. Bukstein).Clinical trial registration information-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00031395.Disclosure: Dr. Palumbo is on the ADHD Advisory Board and the speakers' bureau of McNeil Consumer and Specialty Pharmaceuticals; is a scientific consultant to and principal investigator for Pfizer; is a site investigator for Shire, Noven, Eli Lilly, Organon, and Cephalon; and has received educational grant support from Novartis, McNeil, and Celltech/UCB. Dr. Sallee is a consultant to Shire and Otsuka. Dr. Bukstein is on the speakers' bureaus of McNeil Consumer and Specialty Pharmaceuticals, Shire, and Novartis; is a consultant to Shire, Cephalon, and Forest Research Institute; and receives funding support from Shire, Eli Lilly, and Sanofi Aventis. Dr. Daviss is on the speakers' bureau of Shire Pharmaceuticals. The other authors report no conflicts of interest.

PII: S0890-8567(09)62289-9

doi: 10.1097/chi.0b013e31815d9af7

© 2008 The American Academy of Child and Adolescent Psychiatry. Published by Elsevier Inc. All rights reserved.